Should we be combining local tumor therapies with immunotherapies as standard?

被引：3
|
作者：
Baues, Christian [1 ,2 ,3 ]
Schlaak, Max [1 ,4 ]
von Bergwelt-Baildon, Michael [1 ,5 ,6 ]
Theurich, Sebastian [1 ,5 ,7 ]
机构：
[1] Univ Hosp Cologne, Radio Immune Oncol RIO Consortium, Cologne, Germany
[2] Univ Hosp Cologne, Dept Radio Oncol, Cologne, Germany
[3] Univ Hosp Cologne, CyberKnife Ctr, Cologne, Germany
[4] Univ Hosp Cologne, Skin Canc Ctr, Dept Dermatol & Venereol, Cologne, Germany
[5] Univ Hosp Cologne, Ctr Integrated Oncol CIO Koln Bonn, Dept Internal Med, Cologne, Germany
[6] Univ Hosp Cologne, Dept Internal Med, CII, Cologne, Germany
[7] Univ Hosp Cologne, Dept Internal Med, Canc & Immunometab Res Grp, Cologne, Germany
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 18期
关键词：
abscopal effect; CTLA4; electrochemotherapy; immune checkpoint inhibition; immunogenic cell death; immunotherapy; ipilimumab; local treatment; nivolumab; PD-1; pembrolizumab; radiotherapy; talimogene laherparepvec; T-VEC; ADVANCED MELANOMA; UNTREATED MELANOMA; RADIATION-THERAPY; IPILIMUMAB; NIVOLUMAB; SURVIVAL; RADIOTHERAPY; COMBINATION;
D O I：
10.2217/fon-2017-0150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1573 / 1575
页数：3
相关论文
共 50 条
  • [1] Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
    Kerr, Caroline P.
    Grudzinski, Joseph J.
    Nguyen, Thanh Phuong
    Hernandez, Reinier
    Weichert, Jamey P.
    Morris, Zachary S.
    PHARMACEUTICS, 2023, 15 (01)
  • [2] Biotherapies, immunotherapies, targeted therapies, biopharmaceuticals ... Which word should be used?
    Watier, Herve
    M S-MEDECINE SCIENCES, 2014, 30 (05): : 567 - 575
  • [3] Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
    Ngiow, Shin Foong
    Young, Arabella
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [4] Psychological therapies: could we, should we, come together?
    Loewenthal, Del
    EUROPEAN JOURNAL OF PSYCHOTHERAPY & COUNSELLING, 2008, 10 (01) : 1 - 3
  • [5] Should we refuse requests for complementary therapies?
    Browne, A
    PATIENT EDUCATION AND COUNSELING, 1999, 38 (02) : 167 - 171
  • [6] Combining systemic and local therapies for hepatocellular carcinoma
    Wehrenberg-Klee, Eric
    Goyal, Lipika
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (12): : 976 - +
  • [7] Autoimmune encephalitis: Should we consider third-line immunotherapies earlier?
    Kelly, Mark J.
    Irani, Sarosh R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (05) : 1167 - 1169
  • [8] Professionalism in Medicine: We Should Set the Standard
    Nace, M. Catherine
    Dunlow, Susan
    Armstrong, Alicia Y.
    MILITARY MEDICINE, 2009, 174 (08) : 807 - 810
  • [9] STANDARD-DEVIATION, STANDARD ERROR - WHICH STANDARD SHOULD WE USE
    BROWN, GW
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1982, 136 (10): : 937 - 941
  • [10] Tumor markers: Should we or shouldn't we?
    McCarthy, NJ
    Swain, SM
    CANCER JOURNAL, 2001, 7 (03): : 175 - 177
12345